Serotonin 5-HT3 receptor antagonist. Prepn: H. H. Haeck et al., EP 297651; eidem, US 4939136 (1989, 1990 both to Duphar Int. Res.); I. van Wijngaarden et al., J. Med. Chem. 36, 3693 (1993). Absolute configuration studies: P. G. Jones et al., Acta Crystallogr. E59, o38, o41 (2003). Pharmacology: A. Botella et al., Fundam. Clin. Pharmacol. 12, 619 (1998). Mechanism of action study: K. Hillsley et al., Neurosci. Lett. 278, 137 (2000). Clinical pharmacology: G. Stacher et al., Br. J. Clin. Pharmacol. 49, 429 (2000). Review of development and therapeutic potential: idem, Curr. Opin. Investig. Drugs 2, 1432-1436 (2001); of clinical experience: W. D. Chey, B. D. Cash, Expert Opin. Invest. Drugs 14, 185-193 (2005).
In treatment of irritable bowel syndrome.
Serotonin Receptor Antagonist